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Background: Adverse events (AEs) in acute care hospitals are frequent and associated with significant morbidity,
mortality, and costs. Measuring AEs is necessary for quality improvement and benchmarking purposes, but current
detection methods lack in accuracy, efficiency, and generalizability. The growing availability of electronic health
records (EHR) and the development of natural language processing techniques for encoding narrative data offer an
opportunity to develop potentially better methods. The purpose of this study is to determine the accuracy and
generalizability of using automated methods for detecting three high-incidence and high-impact AEs from EHR
data: a) hospital-acquired pneumonia, b) ventilator-associated event and, c) central line-associated bloodstream
infection.
Methods: This validation study will be conducted among medical, surgical and ICU patients admitted between
2013 and 2016 to the Centre hospitalier universitaire de Sherbrooke (CHUS) and the McGill University Health Centre
(MUHC), which has both French and English sites. A random 60% sample of CHUS patients will be used for model
development purposes (cohort 1, development set). Using a random sample of these patients, a reference standard
assessment of their medical chart will be performed. Multivariate logistic regression and the area under the curve
(AUC) will be employed to iteratively develop and optimize three automated AE detection models (i.e., one per AE
of interest) using EHR data from the CHUS. These models will then be validated on a random sample of the
remaining 40% of CHUS patients (cohort 1, internal validation set) using chart review to assess accuracy. The most
accurate models developed and validated at the CHUS will then be applied to EHR data from a random sample of
patients admitted to the MUHC French site (cohort 2) and English site (cohort 3)—a critical requirement given the
use of narrative data –, and accuracy will be assessed using chart review. Generalizability will be determined by
comparing AUCs from cohorts 2 and 3 to those from cohort 1.
(Continued on next page)* Correspondence: Christian.Rochefort@usherbrooke.ca
1School of Nursing, Faculty of Medicine and Health Sciences, University of
Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
2Centre de recherche de l’Hôpital Charles-LeMoyne, University of
Sherbrooke—Campus Longueuil, 150 Place Charles-LeMoyne, Longueuil, QC
J4K 0A8, Canada
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Rochefort et al. BMC Health Services Research  (2017) 17:147 Page 2 of 9(Continued from previous page)
Discussion: This study will likely produce more accurate and efficient measures of AEs. These measures could be
used to assess the incidence rates of AEs, evaluate the success of preventive interventions, or benchmark
performance across hospitals.
Keywords: Adverse events, Electronic health record, Acute care hospital, Automated detection, Natural language
processing, Patient safety, Data warehouseBackground
Adverse events (AEs) are injuries caused by medical
management rather than by the underlying condition of
the patient [1]. AEs in acute care hospitals are frequent
and associated with significant morbidity, mortality and
costs [2, 3]. For this reason, preventing AEs is a high pri-
ority worldwide [4, 5]. To evaluate the success of pre-
ventive measures, there is a need for accurate, timely
and efficient methods for monitoring AE rates [6, 7].
Moreover, with the growing emphasis on benchmarking
and public reporting of AE data, these methods must
allow for valid inter-institutional comparisons [8, 9].
However, at present, there are no such methods.
Indeed, hospitals typically rely on manual chart review,
prevalence surveys, incident reporting systems or dis-
charge diagnostic codes for monitoring AE rates [10].
Manual chart review is a time-consuming, resource-
intensive and costly process [6, 11]. As a consequence, it
is an impractical means for the routine detection and
hospital-wide monitoring of AEs. Prevalence surveys
similarly lack in efficiency and scalability and are subject
to important inter-observer variations in the reported
AE rates [11, 12]. Incident reporting systems are known
to significantly underestimate the true incidence rate of
AEs [13]. Discharge diagnostic codes have low sensitivity
and positive predictive value (PPV) for detecting AEs
[14]. Moreover, important variations in coding practices
across institutions preclude their use for benchmarking
purposes [14, 15]. Thus, the limitations in existing
methods for measuring AEs have curtailed the ability to
conduct continuous quality monitoring in acute care
hospitals and the capacity to benchmark performances
across institutions.
With the advent of electronic health records (EHR),
and the development of automated methods for encod-
ing and classifying EHR data, an exciting opportunity
has emerged to develop potentially better methods of
AE detection. Moreover, with the growing adoption of
standards for storing and exchanging EHR data across
applications and institutions [16], there is an opportunity
to develop methods of AE detection that are potentially
generalizable; a key requirement to valid benchmarking.
Taking advantage of these new opportunities, re-
searchers have started to develop novel and potentially
more accurate and efficient methods of AE detection,such as the natural language processing (NLP) of clinical
narratives [12, 17, 18]. For instance, in 2012, we received
funding from the Canadian Institutes of Health Research
(CIHR) to examine the accuracy of NLP techniques for
identifying venous thromboembolism (VTE) from elec-
tronic narrative radiology reports. We found that NLP
techniques are highly efficient and accurate in identify-
ing this AE [19, 20]. While VTEs can be objectively de-
tected from a single source of EHR data (i.e., narrative
radiology reports), this is not the case for most AEs (e.g.,
pneumonia). For these events, several sources of EHR
data must be combined to satisfy existing case defini-
tions (e.g. microbiology, laboratory, radiology, vital signs)
[21–23]. However, the accuracy and generalizability of
such AE detection models are unknown [6, 18].
To move the field forward, there is a strong need to
determine the accuracy of AE detection models that in-
tegrate the information from all available EHR data
sources [6]. Moreover, to obtain valid interinstitutional
comparisons, the generalizability of these models to
other acute care hospitals, including both French and
English settings—which is essential given their reliance
on narrative data,—must be established. The proposed
study aims to address these requirements.
Specifically, this study aims to determine the accuracy
and generalizability of using automated methods for de-
tecting AEs from EHR data. Three AEs were selected for
the purpose of this study: a) hospital-acquired pneumo-
nia, b) ventilator-associated events and, c) central line-
associated bloodstream infection. The rationale for
selecting these AEs is provided in the Methods section.
Methods
Settings
This study will be conducted at two leading Canadian
academic health centres: 1) Centre hospitalier universi-
taire de Sherbrooke (CHUS) and, 2) McGill University
Health Centre (MUHC). The CHUS is composed of two
acute care hospitals and has close to 700 beds. It serves
a population of 500,000 people with annual volumes of
32,000 hospitalizations, 27,000 surgical procedures and
4500 intensive care unit (ICU) admissions [24]. The
MUHC is composed of three acute care hospitals, in-
cluding a French site and two English sites, and has
more than 800 adult beds. It serves a population of 1.7
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zations, 33,300 surgical procedures and 6000 ICU
admissions [25].
Design and population
The study population consists of all adult medical, surgi-
cal and ICU patients admitted to the CHUS and the
MUHC between January 1, 2013 and December 31,
2016. Our proposed approach to AE detection model
development and validation builds on and expand our
prior research work in the area [26]. First, we will use a
random 60% sample of all patients admitted to the
CHUS between the aforementioned dates for model de-
velopment purposes (cohort 1, development set) (Fig. 1).
Then, using a random sample of these patients, a refer-
ence standard assessment of their medical chart will be
performed to determine their true AE status (i.e., posi-
tive or negative). Using the manually reviewed cases as
the reference standard, three automated AE detection
models will be iteratively developed and optimized (i.e.,
one for each AE of interest, which are hospital-acquired
pneumonia [HAP], ventilator-associated events [VAE],
and central line-associated bloodstream infection
[CLABSI]). These models will be developed to mirror
published AE definitions (e.g., Centers for Disease Con-
trol and Prevention/National Healthcare Safety Network
[CDC/NHSN] surveillance definitions) [21–23], which
will also guide electronic health record (EHR) data ex-
traction at the CHUS (Table 1). The most accurate
models will then be validated on a random sample of the
remaining 40% of CHUS patients (cohort 1, internal val-
idation set), and a reference standard assessment of the
medical chart will be performed (Fig. 1) [26].
To determine the extent to which these models can
be generalized to other acute care settings (including
both French and English hospitals)—a critical require-
ment given the reliance of these models on narrative
data—, the most accurate models developed andFig. 1 Project designvalidated at the CHUS will be applied to a random
sample of patients admitted to the MUHC French site
(cohort 2, French external validation set) and to the
MUHC English sites (cohort 3, English external valid-
ation set), and a reference standard assessment of the
medical chart will be performed. Prior to applying the
models to data from the MUHC English sites, French
narrative data employed as predictor of AE occur-
rence in the CHUS models will be translated into
English using a previously validated natural language
processing (NLP) approach [27].
Data sources
Data required for developing the AE detection models
will be extracted from the CHUS and the MUHC infor-
mation systems and clinical data warehouses, and will be
linked by unit, patient, and hospital admission date. Spe-
cifically, data will be extracted from eight electronic da-
tabases: 1) radiology, 2) laboratory, 3) microbiology, 4)
pharmacy, 5) vital signs, 6) admission, discharge, and
transfer, 7) intensive care unit, and 8) hospital discharge
abstracts (Table 1). Narrative data from these sources
(e.g., radiology reports) will be converted to numeric
using NLP techniques developed and validated in our
prior research work [19, 20].
Measures
Adverse events
Three potentially preventable AEs were selected for the
purpose of this study: a) hospital-acquired pneumonia
(HAP); defined as an infection of the lung parenchyma
occurring 48 h or more after hospital admission [21], b)
ventilator-associated event (VAE); an AE indicator that
was introduced by the CDC in January 2013 to broaden
the focus of surveillance in ventilated patients from
pneumonia alone to a larger set of physiologically signifi-
cant and potentially preventable complications of mech-
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and, c) central line-associated bloodstream infection
(CLABSI) defined as a laboratory-confirmed blood-
stream infection occurring in a patient with a central
line in place for more than 48 h on the date that the
positive blood culture is identified [23].
These AEs were selected because they are associated
with significant morbidity, mortality, and costs [29–31].
Moreover, these indicators have high incidence rates
compared to other AEs. HAP accounts for 15% of all
hospital-acquired infections and 25% of all ICU-acquired
infections [30]. HAP is estimated to occur at a rate of 5
to 20 cases per 1000 hospital admissions [30]. VAEs are
the most frequent ICU-acquired AEs; occurring in 5.6%
to 10% of mechanically ventilated patients [31]. Lastly,
central lines are the most important cause of blood-
stream infections, with CLABSIs occurring in 2% to 7%
of all catheterizations [32].
Patient demographic and clinical characteristics
Patient demographic characteristics, comorbidities and
severity of illness can influence the likelihood of AE oc-
currence, the accuracy of AE detection models and the
generalizability of these models across institutions [11].
Patient age and sex will be extracted from the discharge
abstract database. Comorbidities will be measured using
the Charlson Comorbidity Index, a weighted index of 17
comorbidities [33]. Comorbidities will be measured at
the time of hospital admission using discharge diagnos-
tic codes from prior hospitalizations since 2008 (i.e., the
earliest date for which complete data is available at the
study sites). Severity of illness in medical and surgical
patients will be measured within 24 h of hospital admis-
sion using the Laboratory-based Acute Physiology Score
(LAPS); a scoring system that integrates information
from 14 laboratory tests into a single continuous vari-
able [34]. Severity of illness in ICU patients will be mea-
sured using the Acute Physiology and Chronic Health
Evaluation (APACHE) III Score; a scoring system that
integrates 12 physiologic measurements [35]. APACHE
III scores are systematically measured at the CHUS and
the MUHC within 24 h of ICU admission and stored in
the ICU database.
Reference standard development and validation
Charts will be reviewed by trained medical chart re-
viewers (MCRs) who will perform chart review using
standardized surveillance definitions (i.e., CDC/NHSN)
[21–23]. MCRs will enter patient AE status (i.e., positive
or negative) in an electronic abstraction form that was
developed during our pilot work [19, 20]. To assess
inter-rater reliability, a random 10% sample of the med-
ical charts will be blindly reviewed by a second MCR,
and intraclass correlation coefficients (ICC) will becomputed. ICC values above 0.75 will be judged as ex-
cellent [36]. To ensure data quality throughout the
study, MCRs will undergo periodic quality assurance
monitoring [26].
AE detection model development and optimization
The automated AE detection models will be developed
in accordance with published methodological guidelines
[37, 38], and will mirror CDC/NHSN surveillance defini-
tions (Table 1) [21–23]. Three successive steps will be
followed, which build on and expand on our prior re-
search work in the area [26]. In Step 1, receiver operat-
ing characteristic (ROC) curves will be used to
determine for selected EHR data sources: a) optimal cut
points for defining the presence of an AE (e.g., using
various thresholds for defining an elevated white blood
cell count, an abnormal ventilator setting or an elevated
body temperature), and b) optimal time window for
measuring these parameters (e.g., requiring a single day
with an elevated white blood cell count versus two or
more consecutive days, requiring only one versus two or
more consecutive chest x-rays showing evidence of
pneumonia) (Table 1) [26]. In addition, ROC area under
the curve (AUC), along with its 95% confidence intervals
(CIs), will be used to assess the accuracy of each individ-
ual data source. To analyse narrative data, we will build
on NLP techniques developed in our prior research work
to identify subsets of words, phrases and patterns in clin-
ical narratives that are significantly associated with the oc-
currence of each AE of interest [19, 20]. In Step 2, three
separate multivariate logistic regression analyses—one for
each AE of interest—will be conducted to assess the incre-
mental effect in detection accuracy of combining EHR
data sources, using the optimal cut points and measure-
ment windows identified in Step 1 [26]. Stepwise and
backward procedures will be used to identify data sources
that are significantly associated with AE occurrence [37].
AUCs along with their 95%CIs will be used to assess the
incremental effect in detection accuracy associated with
the inclusion of a given data source in the regression
model. AUCs across models will be compared [38].
Data sources not significantly associated with AE oc-
currence will be eliminated from the model [26]. In
Step 3, the best regression models identified in Step 2
will be used to assess the incremental effect in detec-
tion accuracy of including patient demographic char-
acteristics, comorbidities and severity of illness [26].
Specifically, the AUCs of regression models including
these characteristics will be compared to those from
the best performing models in Step 2 [38]. During
each of the aforementioned steps, estimates of sensi-
tivity, specificity, positive predictive value (PPV) and
negative predictive value (NPV), along with their 95%
CIs, will be computed [26].
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The best performing models from the development and
optimization steps will be applied to a random sample of
the remaining 40% of CHUS patients (cohort 1, internal
validation set) and their performance will be assessed
using a reference standard assessment of the medical
chart. AUCs from the validation set will be compared to
those obtained during the development and optimization
steps [38]. Estimates of sensitivity, specificity, PPV and
NPV, along with their 95% CIs will be computed for the
best performing models.
To assess the extent to which the best performing
models developed and validated at the CHUS can be
generalized to other acute care hospitals, they will be ap-
plied to a cohort of patients admitted to the MUHC
French site (cohort 2, French validation set) as well as to
a cohort of patients admitted to the MUHC English sites
(cohort 3, English validation set) (Fig. 1). Then, a refer-
ence standard assessment of the medical charts will be
performed at each site for a random sample of AE posi-
tive and AE negative patients. Prior to applying the
models to data from the MUHC English site, French
words used as predictors of AE occurrence in the CHUS
models will be translated into the equivalent English
terms using a validated NLP approach [27]. To deter-
mine if there are any significant differences in the per-
formance of the AE detection models across sites, the
AUCs obtained from cohort 2 and 3 will be compared to
those obtained from the best performing models in co-
hort 1. Lastly, because it is common for the perfor-
mances of prediction models to degrade when validated
in a new patient population, the intercept and the re-
gression coefficients of the CHUS models will be recali-
brated (updated), if necessary, on MUHC data [37].
Sample size requirements
For the development set, assuming an incidence rate of
5.0% for both HAP and CLABSI [30, 32], and of 7% for
VAE [31] a total of 894 AE positive charts (i.e., 298 HAP,Fig. 2 Gantt chart for project timelines298 VAE and 298 CLABSI) and 5662 AE negative charts
is required to generate a 95%CI width of 0.10 around a
sensitivity estimate of 0.90 [39]. For the validation sets,
we will maximize efficiency by using the automated AE
detection models to oversample AE positive patients in
relation to AE negative ones [40]. Assuming the afore-
mentioned incidence rates, a total of 639 AE positive
(i.e., 237 HAP, 165 VAE and 237 CLABASI) and 3099
AE negative charts is required in each validation set to
generate a 95%CI width of 0.10 around a sensitivity esti-
mate of 0.90 that is adjusted for the over-sampling of AE
positive patients [40]. To minimize the costs associated
with performing chart review, all AE negative patients in
the validation sets will be selected so that they are nega-




This study was funded by the CIHR in July 2016. We re-
ceived research ethics approval from the CHUS and the
MUHC in August 2016 and are now ready to initiate
data extraction at the CHUS. This study will be con-
ducted over 4 years. The details of the study timelines
are provided in Fig. 2.
The anticipated contributions
This study aims to produce more accurate and efficient
measures of AEs. These measures could be used to
document the incidence rates of AEs, evaluate the effect-
iveness of interventions targeted at improving patient
safety and monitor progresses through time. In addition,
because these measures are automatable, they offer the
potential to rapidly scan high volumes of EHR data with
minimal human input and at relatively low costs, which
represent major gains compared to using manual chart
review or prevalence surveys. As a result, human re-
sources currently assigned to AE surveillance in acute
care hospitals could be more productively reallocated to
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terventions. Lastly, automation has the potential to
standardize AE surveillance; a net gain over manual ap-
proaches and a critical requirement to valid interinstitu-
tional comparisons. Such comparisons are needed to
define targets for performance improvement, but also to
identify and implement best practices from leaders in
the field.
Potential challenges and mitigation strategies
Based on our prior research work at the CHUS and the
MUHC, we anticipate three potential challenges. First,
EHR data extraction is often delayed by conflicting pri-
orities. To mitigate this challenge, and ensure that the
study is conducted within the proposed timelines, we: a)
are working on AE indicators that are highly relevant to
the CHUS and the MUHC, b) have invited key decision-
makers from these institutions as co-investigators/col-
laborators on this study. These decision-makers have
authority over the data warehouses at the CHUS and
MUCH; the main infrastructure required for supporting
the proposed study. They are also important knowledge
and technology users; bringing practice-relevant know-
ledge to the team. Second, while infection preventionists
(IPs) routinely monitor HAP, VAE and CLABSI rates,
existing data at the study sites is only available for small
subsets of selected patients and time periods (as in most
other hospitals). Moreover, important variations in the
application of surveillance definitions by IPs both within
and across hospitals preclude the use of this data as a
reference standard [7]. For these reasons, we opted to
develop and validate our own reference standard for this
study. Last, the performances of prediction models often
degrade when they are validated in a new patient popu-
lation. To guard against this, and maximize the
generalizability of the AE detection models, we have
planned for model update techniques in the data analysis
steps.
Knowledge translation plan
To facilitate the dissemination and uptake of the new
knowledge that will be generated by this study, our
knowledge translation plan will target four groups. First,
we have partnered with key decision-makers, clinical
leaders and patient safety experts at the CHUS and the
MUHC who are engaged as co-investigators/collabora-
tors on the study, have significantly contributed to its
development and to the selection of high-priority AE in-
dicators. Through such engagement, we aim to develop
practice-relevant and clinically useful AE detection
models. Moreover, based on the results of our pilot work
at these sites [19, 20], we are exploring the possibility of
integrating the AE detection models within quality and
safety dashboards at the CHUS and the MUHC. Thesecould serve as demonstration projects for other hospitals
throughout Canada and abroad. Second, to reach a na-
tional audience of potential knowledge users (i.e., patient
safety experts, infection control professionals), we will
partner with the Communication Services at the Univer-
sity of Sherbrooke to organize and advertise two national
webinars (one in French, the other in English) through
Mybys web-conferencing technologies (www.mybys.com).
These webinars will be tailored to the needs of this audi-
ence and will aim to increase awareness about automated
AE detection using EHR data, while highlighting key mes-
sages and lessons from our research study. Third, we will
organize press conferences to inform the population and
the media about the findings of this study and the value-
added of EHRs for patient safety. Lastly, we will commu-
nicate the findings of this study to academic and research
colleagues through conference presentations and submis-
sion of manuscripts for publication.
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